Last updated: November 4, 2026
Zofran Preservative Free is the injectable ondansetron hydrochloride presentation used primarily in hospitals for chemotherapy-induced nausea and vomiting, postoperative nausea and vomiting, and radiation-associated nausea. Its commercial trajectory is mature and largely genericized. The original branded product no longer has meaningful U.S. exclusivity, while hospital purchasing, generic contracting, supply reliability, and formulation availability determine market performance.
What is Zofran Preservative Free?
Zofran Preservative Free is an injectable formulation of ondansetron hydrochloride, a selective 5-HT3 receptor antagonist. The product is administered intravenously or intramuscularly, depending on the indication and dosage form. The active concentration commonly associated with the injectable product is 2 mg/mL.
The product was developed by Glaxo, later GlaxoSmithKline and now part of Haleon and GSK’s historical pharmaceutical portfolio. FDA approval for Zofran injection dates to the early 1990s. The product was approved for:
- Chemotherapy-induced nausea and vomiting
- Radiotherapy-induced nausea and vomiting
- Postoperative nausea and vomiting
The preservative-free presentation is relevant in hospital settings where single-dose administration, neonatal or pediatric use, and avoidance of antimicrobial preservatives influence product selection. It competes with generic ondansetron injection rather than with a differentiated branded product.
| Product attribute |
Zofran Preservative Free |
| Active ingredient |
Ondansetron hydrochloride |
| Drug class |
5-HT3 receptor antagonist |
| Route |
Intravenous or intramuscular injection |
| Common concentration |
2 mg/mL |
| Main settings |
Hospitals, ambulatory surgery, oncology |
| U.S. regulatory pathway |
Original NDA |
| Current competitive status |
Genericized small-molecule market |
| Biosimilar exposure |
None |
| Principal commercial risk |
Generic price competition and supply disruption |
What is the FDA regulatory status of Zofran Preservative Free?
The original injectable product was approved under an FDA new drug application. Current U.S. commercial status must be separated into three categories: historical FDA approval, active labeling, and actual marketing availability.
FDA approval of an NDA does not require the branded product to remain commercially available. Hospitals may receive ondansetron injection from generic manufacturers even when the original Zofran-branded presentation is absent from active distribution channels. FDA’s Drugs@FDA database and DailyMed labeling identify the approved product history and labeling, while current availability is determined by manufacturer distribution and National Drug Code status.[1,2]
The market now operates primarily through generic ondansetron injection. Common suppliers have included major injectable manufacturers such as Fresenius Kabi, Hikma, Pfizer subsidiary Hospira, Sagent Pharmaceuticals, and other ANDA holders, depending on the period and package configuration.
What formulations are protected by Zofran’s original approval?
Zofran’s historical product family included several dosage forms:
- Tablets
- Orally disintegrating tablets
- Oral solution
- Injectable solution
The preservative-free injection competed with both preserved and preservative-free injectable configurations. In practice, the critical purchasing distinction is often package format rather than brand identity. Hospitals evaluate concentration, vial size, single-dose status, storage requirements, barcoding, 340B pricing, and vendor reliability.
When did Zofran lose exclusivity?
Zofran lost meaningful U.S. market exclusivity many years ago. Ondansetron generics entered the U.S. market after expiration of the principal patent and regulatory exclusivity framework surrounding the original product.
The core U.S. patent protecting ondansetron, U.S. Patent No. 4,695,578, expired in the mid-2000s after accounting for patent-term adjustments and applicable pediatric exclusivity. Patent protection for the original active pharmaceutical ingredient no longer blocks generic ondansetron injection.
| Exclusivity category |
Approximate status |
| Original composition and product protection |
Expired |
| U.S. regulatory exclusivity |
Expired |
| Method-of-use exclusivity for original indications |
Expired or commercially immaterial |
| Formulation protection for standard injection |
No meaningful barrier to approved generics |
| Current biosimilar protection |
Not applicable |
| Current branded generic-entry barrier |
None of material commercial significance |
The exact patent position depends on the dosage form, indication, jurisdiction, and historical patent-term adjustments. That distinction does not change the current commercial conclusion: generic manufacturers can market approved ondansetron injection without infringing an active, commercially controlling Zofran patent estate.
How many patents cover Zofran Preservative Free?
No active U.S. patent estate appears to provide significant protection for the standard preservative-free ondansetron injection market. The original patents covered ondansetron and its pharmaceutical uses, but their expiration removed the primary legal barrier to ANDA competition.
Later patents, if any, would need to cover a specific formulation, manufacturing process, container-closure system, or delivery configuration. Such patents would not automatically protect the broad market for 2 mg/mL ondansetron injection.
The practical patent position is therefore:
- The original active ingredient protection is expired.
- The original therapeutic-use protection is expired.
- Standard injectable ondansetron is exposed to multiple generic suppliers.
- Narrow formulation or manufacturing patents would have limited value unless they controlled a required hospital specification or solved a documented stability problem.
Are there Paragraph IV challenges to Zofran Preservative Free?
Paragraph IV litigation is no longer a central commercial issue for the original Zofran preservative-free injection product. Paragraph IV certifications are generally relevant when an ANDA applicant challenges an unexpired Orange Book-listed patent. Because the principal Zofran patent estate is expired, later generic competition has proceeded mainly through ordinary ANDA pathways rather than through a current branded defense strategy.
Historical generic filings may have included Paragraph IV certifications against patents that were still listed or had not yet expired at the time of filing. Those disputes do not create a current exclusivity barrier for the product.
What is the Orange Book status of Zofran Preservative Free?
The Orange Book remains the relevant source for determining listed patents, therapeutic-equivalence codes, and approved generic competition. Zofran injection was historically associated with an NDA listed for ondansetron injection. The present economic value of the Orange Book listing is limited because the key patent rights have expired and generic ondansetron products have established therapeutic-equivalence pathways.
For commercial analysis, the important Orange Book conclusions are:
- The original NDA does not create continuing market exclusivity.
- Approved ANDA products can compete with the reference product.
- A therapeutically equivalent generic can be substituted under state pharmacy rules, subject to institutional purchasing practices.
- Hospital buyers generally negotiate directly with manufacturers rather than relying on retail substitution alone.
How strong is the patent estate for Zofran Preservative Free?
The patent estate is weak from a current market-protection perspective. Its strength was historically high because ondansetron was a differentiated antiemetic with strong oncology and surgical demand. That strength has ended through patent expiration and broad generic adoption.
| Patent-estate factor |
Current assessment |
| Active ingredient protection |
Weak or expired |
| Standard injection protection |
Weak |
| Method-of-use protection |
Expired for original core indications |
| Manufacturing barriers |
Low to moderate |
| Regulatory barriers |
Moderate for sterile injectables |
| Switching barriers |
Low for hospitals with approved generic supply |
| Pricing power |
Low |
| Litigation leverage |
Low |
Sterile injectable manufacturing creates a regulatory and operational barrier, but it is not equivalent to patent exclusivity. FDA approval requires validated aseptic manufacturing, quality controls, container-closure compliance, and inspection readiness. These requirements limit the number of reliable suppliers but do not preserve branded pricing power.
What generic entry risks exist for Zofran Preservative Free?
Generic entry risk is effectively realized rather than prospective. The relevant risks are now price erosion, supplier consolidation, and shortage-driven substitution.
Price erosion
Hospital buyers typically procure ondansetron injection through group purchasing organizations, direct contracts, wholesalers, and 340B arrangements. Multiple approved suppliers can produce substantial price pressure. The branded Zofran name has limited influence in institutional purchasing where the active ingredient, concentration, and package configuration are equivalent.
Supply interruption
Ondansetron injection has periodically been affected by sterile injectable manufacturing constraints and market-wide shortages. A shortage can temporarily improve utilization or pricing for manufacturers with available inventory, but it does not restore durable exclusivity. Hospitals usually shift between suppliers when a contract manufacturer or primary vendor experiences a disruption.
Package-specific competition
Competition can vary by:
- Single-dose versus multidose packaging
- 2 mL versus larger vial formats
- Preservative-free status
- Barcode and electronic medication administration compatibility
- Wholesaler availability
- Shelf life
- Storage and handling requirements
A supplier with a preferred vial size may obtain a temporary contracting advantage without having patent protection.
What is the financial trajectory for Zofran Preservative Free?
The product’s financial trajectory follows the standard lifecycle of a successful small-molecule hospital drug:
- Rapid adoption after approval
- Expansion across oncology and surgical care
- Peak branded revenue before generic entry
- Abrupt branded revenue erosion after patent expiry
- Mature generic market with low unit prices
- Revenue volatility tied to supply, contracts, and shortages
GSK has not historically reported Zofran Preservative Free as a separate line item in its public financial statements. Public disclosures generally grouped Zofran with broader product portfolios or reported it within therapeutic-area sales. As a result, a precise current revenue figure for the preservative-free presentation cannot be derived from company filings.
The financial exposure is now concentrated in the generic market rather than the original brand owner. Generic manufacturers may generate recurring revenue from large hospital volumes, but margins depend on production costs, contract terms, active pharmaceutical ingredient supply, and the number of competing suppliers.
| Financial period |
Commercial condition |
Expected revenue pattern |
| Pre-generic period |
Branded oncology and surgical use |
High price and strong margin |
| Initial generic entry |
Multiple ANDA suppliers |
Rapid brand erosion |
| Mature generic period |
Institutional contracting |
Low price, high volume |
| Shortage period |
Limited supplier availability |
Temporary price or share improvement |
| Current market |
Commodity-like injectable |
Stable but low-margin revenue |
Which companies challenge Zofran Preservative Free?
Competition comes primarily from generic ondansetron injection manufacturers rather than from branded pharmaceutical companies. The competitive field has included large injectable suppliers and specialty generic manufacturers.
Representative competitive groups include:
- Fresenius Kabi
- Hospira, now part of Pfizer
- Hikma Pharmaceuticals
- Sagent Pharmaceuticals, historically
- Other ANDA-approved sterile injectable manufacturers
The specific active supplier set changes over time because manufacturers discontinue low-margin presentations, transfer products between affiliates, or suspend production after quality or capacity issues.
No biosimilar competitor is relevant. Ondansetron is a chemically synthesized small molecule, not a biologic. FDA competition occurs through ANDAs and therapeutic equivalence, not through the 351(k) biosimilar pathway.
What patent litigation affects Zofran Preservative Free?
Current litigation risk is low compared with the product’s historical litigation profile. The main legal issues associated with Zofran have involved product liability, promotional conduct, reimbursement, and broader commercial disputes rather than an active patent battle controlling preservative-free injection entry.
A historical legal matter with commercial relevance was litigation involving generic competition and the timing of generic ondansetron entry. Those disputes are no longer sufficient to protect the original branded market because the underlying patent exclusivity has expired.
For current investors and licensors, the material legal risks are more likely to involve:
- Sterile manufacturing compliance
- Product recalls
- Labeling deviations
- Supply contracts
- Antitrust issues in hospital contracting
- Product liability
- Shortage-related allocation decisions
What licensing deals affect Zofran Preservative Free?
The product originated within Glaxo’s branded pharmaceutical business. No current licensing arrangement appears to provide an economically meaningful barrier to generic ondansetron injection. Historical development, commercialization, or distribution arrangements may have affected regional sales, but they do not create current U.S. exclusivity.
The commercial value of any license would now depend on manufacturing access, hospital contracts, geographic rights, or supply reliability rather than on the underlying Zofran patent estate.
How does Zofran Preservative Free compare with competing antiemetics?
Ondansetron injection competes with other 5-HT3 antagonists and newer antiemetic regimens. Its principal advantage is familiarity, broad hospital adoption, low cost, and extensive clinical experience. Its limitations include generic pricing, class competition, and the availability of newer agents for highly emetogenic chemotherapy.
| Product or class |
Competitive position versus ondansetron injection |
| Generic ondansetron injection |
Direct substitute |
| Palonosetron |
Longer half-life and use in selected chemotherapy regimens |
| Granisetron |
Direct 5-HT3 class competitor |
| Dolasetron |
Historically relevant, now limited |
| NK1 antagonists |
Used in combination for higher-risk chemotherapy |
| Dopamine antagonists |
Alternative or adjunctive antiemetic therapy |
| Oral ondansetron |
Competes when injection is unnecessary |
The product retains demand because emergency departments, surgical centers, oncology clinics, and inpatient units use ondansetron across a wide range of nausea and vomiting settings.
What generic launch scenarios exist?
The likely current scenarios are operational rather than patent-driven.
Base case
Multiple generic suppliers remain active. Prices stay low, and market share moves through hospital contracts and availability.
Shortage case
One or more major suppliers experience production disruption. Remaining manufacturers gain volume, and hospitals temporarily accept higher prices or substitute vial formats.
Consolidation case
Low profitability causes smaller suppliers to exit. The remaining manufacturers gain greater bargaining power, but the market remains exposed to future shortages.
Brand-revival case
A branded relaunch would face weak economic logic unless it offered a clear advantage, such as a differentiated delivery system, guaranteed supply, specialized packaging, or a new indication. A conventional preservative-free ondansetron injection would not support a strong premium without such differentiation.
What geographic coverage does Zofran Preservative Free have?
Ondansetron is broadly commercialized internationally, but brand status varies by jurisdiction. In many markets, the original brand has been replaced by generic ondansetron products. Geographic commercial value is driven by:
- Local patent expiration
- National reimbursement rules
- Hospital procurement systems
- Registration requirements for sterile injectables
- Local manufacturing capacity
- Tender participation
- Supply reliability
The United States is a mature generic market. Emerging markets may retain brand recognition, but local tender pricing and generic competition still constrain margins.
Key Takeaways
- Zofran Preservative Free is an injectable ondansetron hydrochloride product used mainly in hospitals.
- The original Zofran patent estate no longer provides meaningful U.S. exclusivity.
- Standard preservative-free ondansetron injection is exposed to generic competition.
- No biosimilar pathway applies because ondansetron is a small molecule.
- Current commercial value depends on sterile manufacturing, hospital contracts, package configuration, and supply reliability.
- GSK does not separately disclose revenue for the preservative-free presentation.
- The branded financial trajectory is mature and largely eroded; generic revenue is volume-driven and low-margin.
- Current legal exposure is more likely to involve manufacturing, labeling, supply, and product liability than patent litigation.
- A relaunch would require differentiated delivery, packaging, or supply assurance to justify premium pricing.
FAQs
Is Zofran Preservative Free still commercially available?
The original branded product’s availability varies by market and distribution channel. Generic ondansetron injection is the principal U.S. hospital supply source.
Does Zofran Preservative Free have active U.S. patent protection?
The original U.S. patent protection for ondansetron and its core uses has expired. No broad active patent barrier is expected to block generic standard injection products.
Is ondansetron injection subject to biosimilar competition?
No. Ondansetron is a chemically synthesized small molecule and competes through generic ANDA approvals rather than biosimilar applications.
Can hospitals substitute generic ondansetron for Zofran injection?
Approved therapeutically equivalent generic products can generally substitute for the reference product, subject to institutional formulary rules, state law, purchasing contracts, and product availability.
What could improve the economics of preservative-free ondansetron injection?
The strongest commercial levers are reliable sterile supply, differentiated vial formats, reduced administration waste, improved packaging, and preferred hospital contracts. Patent-based pricing power is no longer the primary value driver.
References
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. National Library of Medicine. (n.d.). DailyMed: Zofran and ondansetron injection labeling. https://dailymed.nlm.nih.gov/
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda
- U.S. Patent and Trademark Office. (1987). U.S. Patent No. 4,695,578: 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one.
- GlaxoSmithKline plc. (Various years). Annual reports and financial statements. https://www.gsk.com/en-gb/investors/financial-results/
- U.S. Food and Drug Administration. (n.d.). Drug shortages. https://www.accessdata.fda.gov/scripts/drugshortages/
